When cost stops being the barrier: The new chapter of Ozempic injection in India | India News – The Times of India

On most evenings at a diabetes clinic, the conversation eventually circles back to the same word: cost. Not calories, not carb counts, cost. For many patients, medicines like Ozempic have hovered in that uncomfortable space between medical breakthrough and financial capacity. Doctors spoke of their benefits with measured optimism; patients listened, did the math, and quietly returned to navigating older drugs, stricter diets, and longer walks.That equation may just change.

With the patent on semaglutide (Ozempic) expiring on March 20, Indian pharmaceutical majors such as Sun Pharma, Zydus Lifesciences, Dr Reddy’s and Natco Pharma are preparing to roll out more affordable versions of the once-exclusive injection. What was until now a premium therapy could soon become a mainstream prescription, potentially reshaping India’s fast-growing anti-obesity and diabetes market.

Image: DD

But cheaper medicine does more than expand access, it indicates a shift in behaviour as well.For years, treatment plans for obesity and type 2 diabetes in India have leaned heavily on lifestyle modification: disciplined diets, exercise regimens, and incremental pharmaceutical support when necessary. Semaglutide, globally celebrated for its dual impact on blood sugar and weight loss, introduced a powerful new lever. Yet its price ensured it remained, for many, a last resort rather than an option they opt for first.As generics enter the scene, doctors may rethink when to prescribe it. Patients who once delayed therapy could start earlier. Weight management clinics may see a surge. And the uneasy balance between lifestyle and medicine, between personal discipline and pharmacological assistance, could tilt in unexpected ways.The question now isn’t just whether semaglutide will be cheaper. It’s whether its affordability will quietly redraw the boundaries of how India treats weight, health, and responsibility itself.

How does Ozempic work?

To understand why semaglutide has generated so much excitement, and debate, it helps to begin with what it actually does inside the body.After we eat, our gut releases hormones called incretins. These chemical messengers tell the pancreas to produce insulin, helping move sugar out of the bloodstream and into cells where it’s needed. They also signal the liver to slow down its sugar production and provide the brain with a simple message: you’ve had enough.Ozempic works by amplifying that natural system.

.

Its active ingredient mimics a hormone known as glucagon-like peptide-1 (GLP-1), which the body produces after meals. In people with type 2 diabetes, this response is often blunted. Semaglutide steps in to strengthen it. It prompts the body to release insulin when blood sugar rises, reduces excess glucose from the liver, and slows the speed at which food leaves the stomach. The combined effect is steadier blood sugar levels and improved HbA1c readings, which essentially helps with long-term glucose control.But the drug’s impact doesn’t stop at sugar.

GLP-1 also acts on the brain’s appetite centres. It signals satiety, that subtle sense of fullness that tells one to put the fork down. By creating a more stable and longer-lasting version of this hormone, semaglutide extends that feeling. For people with obesity, that shift can be mean a lot. The constant mental battle around food quietens. Weight loss becomes less about incessant restraint and more about biology working in their favour.

Lower prices, wider access — and a market set to surge

More players are lining up to join the fray in the coming months, and with each new entrant, the pressure on prices is expected to mount. Until now, India’s weight-loss drug segment has largely been the playground of high-priced innovator brands, accessible to only a few. That exclusivity may not last much longer.Industry watchers estimate the current weight-loss market at around Rs 1,400 crore, and they believe it could double within a year if prices soften and supply widens. The appetite, both medical and consumer, clearly exists.The momentum isn’t limited to obesity drugs alone. The broader anti-diabetic therapy market grew more than 15% in January, according to data from research firm Pharmarack, driven largely by newer, premium treatments. Among them is Mounjaro from Eli Lilly, which clocked Rs 112 crore in sales — a sign that patients and doctors are willing to embrace innovation, even at a higher price point.“The patent expiry is going to affect the market a lot. The expiry is set to take place on the 20th and by 21st we have received a report that 5 different semaglutides are going to be launched,” said Raman Nath of Nath medicines.What changes now is the equation between demand and affordability. If generics bring costs down meaningfully, these medicines could shift from being niche, urban prescriptions to more mainstream therapies. And with that shift, the conversation around weight and diabetes management in India may become less about who can afford cutting-edge care — and more about how widely it can be used.“Doctors prescribe drugs like this based on the economic background of the patients. If they see that the patient is well-off, they would prescribe drugs like Ozempic, otherwise they would prescribe cheaper alternatives,” added Raman.

Beyond weight loss: The body image question

Beyond clinics and balance sheets, another, quieter debate is unfolding, one about mirrors, self-worth and the meaning of acceptance.In recent months, conversations around GLP-1 drugs like Ozempic have drifted beyond blood sugar levels and BMI charts. On social media panels and television debates, some commentators have suggested that if weight can be medically reduced, movements centred on body acceptance may begin to lose urgency. The implication is subtle but powerful: if body size is seen as easily changeable with an injection, then living in a larger body risks being framed as a choice rather than a complex mix of biology, environment and circumstance.For years, the body positivity movement has argued for dignity and inclusion regardless of size. It pushed back against the idea that worth is measured in kilograms. But as drugs like semaglutide become more visible, and potentially more affordable, public perceptions and attitudes may shift. If thinness starts to look medically attainable, will social tolerance shrink?

These drugs help regulate appetite and blood sugar; they do not directly treat shame, stigma or years of internalised criticism. Research has long shown that body size and body image are closely linked. It is not surprising, then, that some people may hope weight loss will also quiet the harsh inner voice or soften the way the world responds to them.Yet access remains uneven, outcomes vary, and no injection can fully untangle the emotional layers tied to food and appearance. As semaglutide becomes more mainstream, India may find itself navigating not just a medical shift, but a cultural one, balancing the promise of better health with the need to preserve empathy, dignity and choice for bodies of every size.“In this country, two kinds of medicines sell the most. One is to get fair and one is to get slim. Ozempic helps with the slimming part. People rarely to want to change their lifestyles. To get thinner you have to bring a lot of changes and be mindful about how you live, what you eat. Ozempic has made it easier to lose weight that is why people tend to consume it more,” Raman said.

The risk of misuse

Originally designed to treat type 2 diabetes, these medications have quickly acquired a second identity, as powerful tools for weight loss. For many patients, the results have felt dramatic, even life-changing, achieving reductions that older diets, pills and fitness fads rarely delivered. It’s no surprise they’re being described as game changers.But as their popularity grows, so do the questions.Most GLP-1 drugs are taken as a once-a-week injection, self-administered in the arm, thigh or abdomen. Treatment typically begins with a low dose that is gradually increased. Within weeks, many users notice a shift: cravings dull, portions shrink, the constant mental chatter around food softens. For some, the scale begins to move for the first time in years.

AI generated image

Yet doctors stress that these medicines are not magic, and not meant to be casual lifestyle accessories. Weight often returns within a year of stopping the drug, as the body’s biological drive to regain lost weight reasserts itself. Without regular exercise, particularly strength training, patients can lose muscle along with fat, a concern in a country where diets are often high in carbohydrates and low in protein.“It’s indicated for weight loss therapy but should be taken only under medical guidance. The potential for misuse is always there if the sale is not restricted,” said Dr Arun Moondhra Senior consultant physician at Sant Parmanand Hospital Civil Lines.There are other limits, too. Not everyone responds to GLP-1 therapy, and many people hit a plateau after losing around 15% of their body weight. Side effects are usually manageable, nausea, bloating, diarrhoea, but rarer complications such as gallstones or pancreatitis can occur. Prolonged, unsupervised use carries its own risks.Dr Moondhra also stressed that the use of semaglutide is going to increase manifold once cheaper generics are available.